pipette
ENEnglish

Clinical utility of plasma APOE proteotyping for Alzheimer's disease risk and prognosis

R. Shi, L. T. Choity, M. F. Farinas, X. Zeng, J. E. Emanuel, A. Saeed, S. E. Reis, O. L. Lopez, M. I. Kamboh, A. D. Cohen, A. G. Gildengers, K. A. Wilckens, T. K. Karikari

PreprintUso en el mundo real

En palabras de los autores

Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder strongly influenced by genetic factors, with apolipoprotein E (APOE) {epsilon}4 allele being the most established risk variant. Although DNA-based genotyping remains standard, plasma proteotyping may provide scalable, isoform-specific alternatives. Methods: Plasma APOE4 protein were quantified using the NULISAseq CNS panel across four cohorts (ADRC, HeartSCORE, LATTICE, and ALPS). DNA-based APOE genotyping was the reference standard. Proteotyping thresholds for APOE {epsilon}4 carrier status and copy number were derived in ADRC and externally validated in the other cohorts. Logistic, proportional-odds, and Cox proportional-hazards models compared genotype- and proteotype-defined groups in relation to amyloid positivity, cross-sectional CDR global scores, and time to CDR-SB worsening, respectively. Results: Plasma APOE4 accurately classified APOE {epsilon}4 carrier status in ADRC (AUC=0.977, 95%CI 0.967-0.985; threshold 5.78 NULISA protein quantification [NPQ] value) and achieved near-perfect external validation in HeartSCORE, LATTICE, and ALPS (all AUCs=1.000, 95%CI 1.000-1.000). Plasma APOE4 also well-differentiated heterozygous from homozygous {epsilon}4 carriers (ADRC AUC=0.879, 95%CI 0.834-0.921; threshold 12.23 NPQ value). Genotype- and proteotype-defined {epsilon}4 carrier status showed similar associations with amyloid positivity (OR=4.40 vs 4.45), higher CDR global scores (OR=1.50 for both), and CDR-SB worsening (HR=1.22 for both). Discussion: Plasma APOE4 proteotyping accurately distinguished genotype-defined APOE {epsilon}4 carrier status and copy number while demonstrating AD-related associations comparable to DNA genotyping.

Resultado principalEl resumen no menciona limitaciones.

Apareció: lunes, 12 de octubre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.08.26364972